By efrat|2024-05-29T06:46:47+00:00June 2nd, 2024|All|Comments Off on June 3rd 2024- Prof Saad Usmani- CD8 Effector T Cells Enhance Teclistamab Response in BCMA-Exposed and -Naïve Multiple Myeloma
By efrat|2024-05-21T07:05:01+00:00May 23rd, 2024|All|Comments Off on May 24th 2024- Dr. Ruth Namazzi- Hydroxyurea reduces infections in children with sickle cell anemia in Uganda
By efrat|2024-05-15T11:09:33+00:00May 19th, 2024|All|Comments Off on May 20th 2024- Dr. Lorenz Bastian- Developmental trajectories and cooperating genomic events define molecular subtypes of BCR:ABL1-positive ALL
By efrat|2024-05-09T09:19:49+00:00May 13th, 2024|All|Comments Off on May 14th 2024- Prof. Didier Blaise- Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
By efrat|2024-05-02T09:07:03+00:00May 6th, 2024|All|Comments Off on May 7th 2024- Prof. Ibrahim Yakoub-Agha- Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
By efrat|2024-04-30T07:00:18+00:00April 30th, 2024|All|Comments Off on April 30th 2024- Dr. Fadi Haddad & Prof. Elias Jabbour- Phase 2 Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission
By efrat|2024-04-14T09:41:37+00:00April 16th, 2024|All|Comments Off on April 17th 2024- Prof. Nigel Russell- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
By efrat|2024-04-08T07:25:13+00:00April 9th, 2024|All|Comments Off on April 10th 2024- Dr. Ofir Wolach- Molecular MRD is Strongly Prognostic in Patients with NPM1-Mutated AML Receiving Venetoclax-Based Nonintensive Therapy
By efrat|2024-03-20T09:54:58+00:00March 24th, 2024|All|Comments Off on March 25th 2024- Prof. Olaf Penack- Prophylaxis and Management of Graft-Versus-Host Disease After Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation
By efrat|2024-03-12T14:17:08+00:00March 19th, 2024|All|Comments Off on March 20th 2024- Prof. Michael Schmitt – Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial
